Q1 Results Presentation May 29, 2025 1 Cautionary Statement Regarding Forward-Looking Information This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions to identify forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding our 2025 a ...

Record first quarter net sales of $1.1 billion, up 8% from last year, exceeding outlookNet sales growth across regions, with Americas up 7%, EMEA up 12% and APAC up 5%Brand performance led by Hollister brands’ growth of 22% with Abercrombie brands down 4% compared to last yearProfitability exceeds company outlook with operating margin of 9.3%, earnings per share of $1.59Repurchased 2.6 million shares for $200 million, representing 5% of shares outstanding at February 1, 2025 NEW ALBANY, Ohio, May 28, 2025 ( ...

Core Viewpoint - VNET Group, Inc. reported strong financial results for the first quarter of 2025, driven by significant growth in its wholesale IDC business and effective execution of its dual-core strategy [2][11][25]. Financial Highlights - Total net revenues increased by 18.3% year-over-year to RMB2.25 billion (US$309.5 million) from RMB1.90 billion in the same period of 2024 [6][11]. - Net revenues from the IDC business rose by 27.8% to RMB1.64 billion (US$226.2 million) from RMB1.28 billion in the same period of 2024 [12]. - Wholesale revenues surged by 86.5% to RMB673.2 million (US$92.8 million) from RMB361.0 million in the same period of 2024 [17]. - Retail revenues increased by 4.8% to RMB968.3 million (US$133.4 million) from RMB923.7 million in the same period of 2024 [17]. - Adjusted EBITDA grew by 26.4% year-over-year to RMB682.4 million (US$94.0 million), with an adjusted EBITDA margin of 30.4%, up from 28.4% in the same period of 2024 [20]. Operational Highlights - As of March 31, 2025, wholesale capacity in service increased by 88MW quarter-over-quarter to 573MW, with utilized capacity reaching a record high of 437MW [2][6]. - The utilization rate of wholesale capacity was 76.2% as of March 31, 2025, compared to 72.6% as of December 31, 2024 [6][12]. - Total capacity committed was 571MW as of March 31, 2025, with a commitment rate for capacity in service of 99.7% [6][12]. Business Outlook - The company expects total net revenues for 2025 to be between RMB9,100 million to RMB9,300 million, representing year-over-year growth of 10% to 13% [25]. - Adjusted EBITDA is projected to be in the range of RMB2,700 million to RMB2,760 million, indicating year-over-year growth of 11% to 14% [25].

Core Insights - Heico Corporation reported $1.1 billion in revenue for the quarter ended April 2025, marking a year-over-year increase of 14.9% and an EPS of $1.12 compared to $0.88 a year ago, exceeding Zacks Consensus Estimates [1] - The revenue surprise was +3.72% over the consensus estimate of $1.06 billion, while the EPS surprise was +9.80% over the consensus estimate of $1.02 [1] Financial Performance Metrics - Net Sales for the Electronic Technologies Group (ETG) reached $342.17 million, exceeding the average estimate of $334.72 million, representing a year-over-year increase of +7.2% [4] - Net Sales for the Flight Support Group (FSG) were reported at $767.07 million, surpassing the average estimate of $734.76 million, with a year-over-year change of +18.5% [4] - Corporate & Intersegment reported net sales of -$11.42 million, better than the average estimate of -$13.49 million, reflecting a +2.3% year-over-year change [4] - Operating income for the Flight Support Group was $184.98 million, exceeding the average estimate of $170.16 million [4] - Operating income for Electronic Technologies Group was $77.88 million, slightly below the average estimate of $81.52 million [4] - The stock has returned +8.4% over the past month, outperforming the Zacks S&P 500 composite's +5.2% change [3]

Eagle Materials (EXP) reported $470.18 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 1.4%. EPS of $2.08 for the same period compares to $2.24 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $477.78 million, representing a surprise of -1.59%. The company delivered an EPS surprise of -11.11%, with the consensus EPS estimate being $2.34.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wal ...

Bank OZK (OZK) reported $409.23 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 0.8%. EPS of $1.47 for the same period compares to $1.51 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $398.81 million, representing a surprise of +2.61%. The company delivered an EPS surprise of +3.52%, with the consensus EPS estimate being $1.42.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stree ...

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 were $8,600,000, representing a 9% increase from the same period last year [5][12] - Net loss for Q1 2025 was $4,200,000 or $0.47 per share, compared to a net loss of $10,400,000 or $2.88 per share for the prior year [15] - Adjusted EBITDA decreased from $4,600,000 in Q1 2024 to $4,400,000 in Q1 2025 [15][16] Business Line Data and Key Metrics Changes - Ameluz sales increased by $500,000 due to a higher unit price and the launch of the RotoLED XL lamp, which generated $200,000 in sales [12] - Total operating expenses decreased to $13,100,000 in Q1 2025 from $13,400,000 in Q1 2024 [12][13] - Cost of revenues decreased by $900,000 or 22.1% compared to last year, attributed to a reduced cost structure under the Ameluz license [13] Market Data and Key Metrics Changes - The company achieved a significant milestone with the granting of a patent for a new formulation of Ameluz, providing protection until December 2043 [6][7] - The enrollment of the final patient in the Phase three clinical trial for Ameluz was announced, aiming to extend the label for treatment beyond the face and scalp [8] Company Strategy and Development Direction - The company aims to achieve record revenues in 2025 without increasing costs, supported by past investments and sales force effectiveness [5] - Future goals include expanding Ameluz's applications to treat superficial basal cell carcinoma and moderate to severe acne, addressing significant medical needs [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving breakeven as quickly as possible, highlighting improved gross profit and reduced operating expenses [11] - The company is committed to exploring additional applications for Ameluz beyond actinic keratosis, indicating a proactive approach to growth [9] Other Important Information - Cash and cash equivalents as of March 31, 2025, were $1,800,000, down from $5,900,000 as of December 31, 2024 [16] - Inventory on hand was $6,500,000 compared to $6,600,000 as of December 31, 2024 [16] Q&A Session Summary Question: How many LAMP units were sold in Q1 2025? - The company placed 18 XL lamps in Q1 2025 [19][20] Question: Is there any sales force attrition affecting expenses? - There has been some turnover, but the company is committed to reorganizing the team for efficiency [24] Question: What is the status of reimbursement for the three-tube indication? - The company has ensured that Medicare covers the three-tube indication, with no reported refusals from doctors [29]

SWK Holdings (SWKH) Q1 2025 Earnings Call May 16, 2025 10:00 AM ET Company Participants Susan Xu - Director - Investor RelationsJody Staggs - CEO & PresidentAdam Rice - CFO Conference Call Participants None - Analyst Operator Day, everyone. Welcome to the SWK Holdings First Quarter twenty twenty five Conference Call. At this time, all participants have been placed on a listen only mode, and the floor will be open for questions and comments after the presentation. It is now my pleasure to turn the floor over ...

Nasdaq: PAVM LISHAN AKLOG, MD Chairman & CEO DENNIS MCGRATH President & CFO Disclaimer 2 ▪ This presentation may contain certain forward-looking statements related to PAVmed Inc. or Lucid Diagnostics Inc. (the "Companies") that involve risks and uncertainties. ▪ Actual results and events may differ significantly from results and events discussed in forward- looking statements. ▪ Factors that might cause or contribute to such differences include, but are not limited to, those discussed in "Risk Factors" in t ...

Ondas Holdings Inc. (NASDAQ:ONDS) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Eric Brock - Chairman of the Board, President and Chief Executive Officer Neil Laird - Interim Chief Financial Officer, Treasurer and Secretary of the Company Oshri Lugassy - Co CEO, Autonomous Systems Markus Nottelmann - CEO, Ondas Networks Conference Call Participants Maxwell Michaelis - Lake Street Capital Markets Glenn Mattson - Ladenburg Thalmann Matthew Galinko - Maxim Group Mike Latimore - ...